. The DRB1*06 type was positively related to the IL-10 production in response to the LSA-CTL peptide, and responders presented mainly A*2. The specificity A*10 was negatively associated with the cellular response to the LSA-J peptide. These results suggest a degree of genetic regulation of specific immune responses by HLA-A, operating at the pre-erythrocytic stage of development of P. falciparum in this Central African population. Genes and Immunity (2001) 2, 4-10.
Introduction
Individual susceptibility to malaria is thought to be influenced by host genotype as well as by parasite-specific immunity. The extent to which host genotype limits the spectrum of possible immune responses may influence the outcome of infection, and has consequences for vaccine design. 1 Twin studies have highlighted the importance of major histocompatibility complex (MHC) as well as non-MHC genes in determining both susceptibility to clinical malaria and immune responsiveness to defined malaria antigens. [2] [3] [4] [5] Thus, specific human leukocyte antigen (HLA) genotypes have been found to affect susceptibility to severe, 6, 7 but not to mild malaria, 8, 9 whilst associations between HLA types and specific T helper cell or antibody responses to defined malarial antigens have been reported by some [10] [11] [12] but not other studies. 9, 13 Through the use of whole genome genetic linkage studies of families, combined with candidate gene analysis, non-MHC genes associated with malaria are currently being mapped and identified. 14, 15 The great number and complexity of HLA antigens makes it difficult to detect convincing associations with the clinical expression of malaria and/or with anti-malarial immune responses, but such studies should be pursued as long as the balance between MHC and non-MHC genes in the regulation of such responses has not been clearly established.
As many of the malaria vaccines currently under development are subunit vaccines reproducing isolated fragments of parasite antigens, it is important to characterize the function of the responses triggered by the Tand B-cell epitopes included in candidate antigens, as well as to evaluate the impact of host genetic factors on these responses. The Liver Stage Antigen-1 (LSA-1) of Plasmodium falciparum is namely a vaccine candidate of interest, eliciting in humans a wide range of immune responses in vitro including reactivity against T and B cell epitopes. [16] [17] [18] [19] [20] It stimulates CTLs and IFN-␥ in naturally exposed individuals, 17, 21 and HLA-B*53 has been found associated with naturally acquired resistance to severe malaria in some but not all studies. 21, 22 We undertook a prospective longitudinal study, over a 1-year period, in schoolchildren living in an area of Gabon where malaria is highly endemic, in order to examine the relationships between malaria prevalence and malaria-related morbidity. 23 In addition, we investigated the associations between disease susceptibility and immune responses directed to synthetic peptides from LSA-1. 24 According to the peptides, the results showed that protection against malaria attacks was associated with higher lymphoproliferative responses after specific stimulation in vitro, as well as with elevated plasma antibody levels. In the study described here, we focused our interest on the analysis of the relationships between the immunologic data recorded for each child and their corresponding HLA class I and II alleles.
Results
A cellular response to a given peptide was defined in our study as the presence of a response to at least one of the following markers of the lymphocyte activity: lymphoproliferation or production of selected cytokines. According to this definition, a mean rate of 68.3% of subjects presented a cellular response to a given peptide. Except for IL-2, the profiles of LPA and cytokine responses were similar for all peptides (Figure 1 ). In general, higher levels of cytokine production were found for TNF-␣, IL-2 and IL-6 (median values Ͼ5 pg/ml) than for IFN-␥ and IL-10 (median values Ͻ3 pg/ml).
The aim of our study was to focus on the importance of HLA class I and class II alleles on the immunologic status of the children. In this Gabonese population we detected 9 HLA-A, and 21 HLA-B specificities, as well as 19 DRB1 (grouped into 10 generic types), 7 DQA1, 12 DQB1 and 16 DPB1 alleles ( Table 1 ). The most prevalent specificities or alleles for each locus were A*19 (29.9%, mainly represented by A*30), B*17 and B*70 (10.4%), DRB1*05 (29.7%), DQA1*0102 (46.5%), DQB1*0602 (39.2%) and DPB1*0402 (29.0%). We found four signifi- Figure 1 Levels of lymphoproliferation (n = 229) and cytokine production (n = 103) in response to peptides from LSA-1 in Gabonese children. Results are the differences between stimulated and unstimulated wells and are expressed as median values (25th-75th percentiles) of responders. Leucoagglutinin (La, 10 g/ml) and tuberculin purified protein derivative (PPD, 10 g/ml) were used as control antigens.
Genes and Immunity cant associations involving the loci HLA-A, -DRB1 and -DQB1 and the T cell reactivity to all three peptides from LSA-1. As strict conditions were assigned to the analysis involving HLA due to the unavoidable large number of hypothesis tests to be done, only HLA I and II alleles or specificities with a minimum count of 12 in the population sample were considered (ie, 29 out of 72), leading to a theoretical number of 609 tests. In fact, 215 tests were effectively done, due to the observance of a minimum size of six in each square of contingency tables. Thus, the four associations which were observed exceeded in size the number of two associations which might have been obtained by chance at a P level of 0.01, validating to a great extent the meaningfulness of our results. In detail, positive associations were observed between HLA-DRB1* 06 (represented at 66% by DRB1*1301-6), -DQB1*0201 and -DQB1*0301 and defined cytokine production in response to peptides LSA-Rep and LSA-CTL (Chi-square test, P from 0.002 to 0.009), and a negative association was observed between HLA-A*10 and the cellular response to LSA-J (Chi-square test, P = 0.008) ( Table 2 ). The search for HLA class I specificities preferentially linked to the HLA class II alleles found associated with specific immune responses revealed that among subjects presenting with the allele DQB1*0301, a greater number of those presenting the specificity A*19 were IFN-␥ producers in response to LSA-CTL than others (Fisher's exact test, P = 0.026) ( Table 3) . A similar observation could be made for children with both DQB1*0201 and A*19 or B* 53 who produced IL-6 in response to LSA-Rep (Fisher's In bold: Alleles retained for analysis, as у12, for 82 HLA class I-and 103 HLA class II-typed subjects with immunological investigations. ++ is positive for both HLA allele and immune response, +− is positive for HLA allele but negative for immune response, −+ is negative for HLA allele but positive for immune response, −− is negative for both HLA allele and immune response; OR, odds ratio; CI, 95% confidence interval. a Immune response stated as: immunological marker or status of T cell reactivity/peptide in concern. b P value of the Chi-square test (P Ͻ 0.01 significant). exact test, P = 0.006 and 0.048, respectively), as well as for those with both DRB1*06 and A*2 who produced IL-10 in response to LSA-CTL (Fisher's exact test, P = 0.029).
When related to clinical protection, the carriage of a particular HLA class I or class II specificity or allele was not directly associated with protection (Fisher's exact test, all P у 0.05). Nevertheless, as 76 children among the 103 enrolled in the immunological assays were clinically classified (38 as unprotected and 38 as protected children), 25 we found that 37% of subjects carrying the HLA-DQB1*0301 allele were both clinically protected and IFN-␥ responders to LSA-CTL vs 16% of protected and non responder subjects (Fisher's exact test, P = 0.07). Conversely, among subjects carrying HLA-A*10, there was a tendency for clinical protection to be associated with the absence of a cellular response to LSA-J, as 34% of them were both clinically protected and cellular nonresponders to LSA-J vs 14% of protected and cellular responder subjects (Fisher's exact test, P = 0.06).
Discussion
The study described here aimed to investigate the interactions between HLA class I and II alleles and immunologic parameters recorded among schoolchildren in Gabon. It should be noted that the distribution of class II alleles is in very good agreement with those reported in earlier studies of Gabonese populations. 26, 27 The assessment of specific immune responses to peptides from the LSA-1 antigen from P. falciparum revealed that an average of 32% of the subjects did not present any cellular response to a given peptide. This finding could indicate an individual capacity, eventually under genetic control, to develop an immune response to the particular epitopes studied. Other studies have reported similar or greater levels of non-responsiveness to peptides derived from parasite antigens. 17, 28 Although the ability of an individual's peripheral blood mononuclear cells (PBMC) to respond to a given molecule may not be revealed in a single cross-sectional study such as that described here, 29 similar levels of cellular non-responsiveness to peptides from P. falciparum were also observed after repeated immunologic measures. 9 Despite the importance afforded to the contribution of non-MHC genes to the regulation of specific immune responses in malaria, 2 numerous studies have been conducted with the aim of identifying MHC-encoded genes influencing specific acquired anti-malarial immunity. [10] [11] [12] Here, we report positive associations involving DRB1 or DQB1 alleles and defined cytokine production in response to peptides from LSA-1. One of these associations was reinforced by the observation that a majority of individuals with the DQB1*0301 allele, and who produced IFN-␥ to LSA-CTL, were clinically protected, suggesting a protective function of the IFN-␥ response to this particular epitope. This observation extends our previous finding of a positive association between the level of lymphoproliferation to LSA-CTL and protection from clinical malaria. 24 Moreover, IFN-␥ is thought to be the most potent cytokine acting directly upon P. falciparum liver-stages, 30 and our own recent study reported that the in vitro production of IFN-␥ by peripheral blood mononuclear cells, in response to the LSA-J and LSA-CTL peptides from LSA-1, was related to resistance to re-infection with P. falciparum. 20 The levels of IFN-␥ produced in vitro in response to the peptides used in the study described here were low (median values below 3 pg/ml), which could indicate that the schoolchildren under investigation have already reached a status of immunity associated with down-regulated IFN-␥ responses. 31 Of interest, the ability of these children to mount an IFN-␥ response to LSA-1 appears to play a more important role than the level of the IFN-␥ produced. There are numerous potential sources of the IFN-␥ produced in response to LSA-1. Among them, HLA class I-restricted CD8 + cytotoxic T lymphocytes may exert protective effects, as described for HLA-B*53-restricted cytotoxic T lymphocytes recognizing specifically the nonamer peptide ls6 (LSA-CTL). 21 Interestingly, our report is not the first to suggest the existence of an HLA class IIassociated polymorphism in IFN-␥ production. Indeed, a previous study reported results of whole blood mixed lymphocyte reactions performed in Caucasians, which revealed that HLA-DR1, 2 or 6 and HLA-DQ1 serological specificities were associated with the generation of significantly higher mean IFN-␥ levels than DR3, 4, 5 or 7 and DQ2 or 3. 32 The fact that all DR specificities associated with high IFN-␥ exhibit linkage disequilibrium with DQ1 led the authors to suggest that the primary association of high IFN-␥ production was with DQ1, rather than the individual DR alleles. Our finding of a positive association between the DQB1*0301 allele (belonging to DQ3 serological specificity) and IFN-␥ response to stimulation by the LSA-CTL peptide does not seem to confirm this previous result, but important differences between both studies may explain this apparently discrepant result (differences in ethnic groups and consequently in HLA allelic distribution as well as values of linkage disequilibrium, differences in the immunological assays performed, differences in the qualitative or quantitative mode of expression of cytokine results). It remains that both studies suggest the existence of a relationship between HLA alleles and IFN-␥ production.
It was striking in our study to observe associations involving HLA class II alleles and immune responses to a liver stage antigen, but the finding of a preferential combination of definite HLA class I specificities with each of these alleles among immune responders suggested that the A*19, A*2 or B*53 specificities involved might be themselves implicated directly in the peptide recognition. We are aware that the greatest care must be taken in interpreting such associations, in that some of them might have been found spuriously significant, such as the association between carriers of both HLA-B*53 and -DQB1*0201 and the IL-6 response to LSA-Rep, B*53 having convincingly been shown to recognize the lonely LSA-CTL peptide. 21 To date, only CTL peptides from the circumsporozoite protein (CS), the thrombospondinrelated anonymous protein (TRAP) and the sporozoite threonine and asparagine rich protein (STARP) from P. falciparum have been found to be HLA-A*2 restricted, and no HLA-A*19 restricted recognition of CTL peptides from P. falciparum has been described. 33 For this reason, we searched for the presence on HLA-DQB1*0301 of any peptide binding motif that could be consistent with LSA-CTL peptide sequence, but we did not find such motif prediction. 34 This observation reinforced our suggestion of a preferential role in the peptide recognition of the A*19 specificity, which was found statistically combined to DQB1*0301 among IFN-␥ responders to LSA-CTL. We know that the biological relevance of this suggestion needs to be established by, either the demonstration of a compatibility between LSA-CTL peptide sequence and one of the alleles belonging to the A*19 serological specificity, and/or the description of a linkage disequilibrium between DQB1*0301 and at least one allele from the A*19 specificity, using a genetic analysis of extended HLA class I and II haplotypes. HLA class II polymorphisms among the villagers of Dienga, who all belong to the Banzabi ethnic group of Bantu origin, were analyzed in an earlier study. 35 This showed that the three-locus haplotype DRB1*1501-3-DQA1*0102-DQB1* 0602 was present at a high frequency rate (31%), revealing this as a particular genetic marker of this popu-lation group, but none of these prevalent alleles was found related in the present study to particular immune responses to LSA-1.
Our second main observation was the presence of a negative association between the specificity HLA-A*10 and the cellular response to LSA-J. The fact that a higher proportion of those carrying the specificity A*10, and who were also non responders to LSA-J, were clinically protected, adds a further layer of complexity to this observation. HLA class I molecules have been shown in general to bind short peptides in the range of 8 to 10 residues, but the binding of 20-mer peptides from the CS protein of P. falciparum has been described. 36 In the same way, antigen presentation by HLA class I molecules generally induces the activation of CD8 + T cells into CTL, but CD8
+ activated T cells are also able to display Th2 helper functions. 37 We therefore speculate that the 24-mer peptide LSA-J may contain HLA class I-restricted epitopes, which may contribute to the regulation of the T cell responses directed to this antigen. A separate study conducted in the same village aimed to identify the immunologic factors associated with resistance to re-infection with P. falciparum after an anti-malarial cure in individual children. This showed that the presence of anti-LSA-J antibodies was related to resistance to re-infection. 38 The contrasting observations of these two studies, involving the same LSA-J peptide, may relate to the different arms of the immune response investigated (T cell reactivity in one case and anti-peptide antibodies in the other), and that these responses were related with different criteria of clinical protection (presence of at least one malaria attack during an active survey in one case and resistance to reinfection after treatment in the other). Lastly, children enrolled in the study of Domarle et al. 38 were young children specifically recruited in nuclear families and thus the sample might present a skewed distribution of the HLA types (and particularly of the specificity A*10) that obscured this relationship.
These findings clearly show that the locus HLA-A and particularly the specificities A*2, A*10 and A*19 are involved in the regulation of the cellular immune responses directed to distinct epitopes from LSA-1. In a study in Papua New Guinea, resistance to P. falciparum infection correlated with CD8 + T-cell IFN-␥ responses to an LSA-1 epitope (residues 84-107) that contained an HLA-A*11-restricted sequence determined by assembly assays. 16, 39 Since A*11 was present at a high frequency in this population (40%), the authors suggested that, as with B*53 responses to LSA-1 in The Gambia, P. falciparum may have driven genetic selection of certain HLA haplotypes. Similar conclusions may be applied to our Gabonese population sample, where A*19 and A*10 are the most frequent specificities (30% and 20% respectively) of the HLA-A locus, whilst A*11 (1.2%) and B*53 (6.1%) are poorly represented. According to the last data compiled on HLA frequencies in sub-Saharan Africa, southern and central Africans exhibit higher A*10, as well as higher A*29 and A*30 (which belong both to the more prevalent sub-specificities of A*19) frequencies than west Africans. 40 A more accurate characterization of the genetic diversity of HLA among central African populations would result from a greater number of descriptive genetic studies, only Zairean, Bubi from Equatorial Guinea and Banzabi (in the present work) ethnic groups having been reported to date. 40 This would allow more convincing conclusions to be drawn on the possible impact of the common HLA alleles on susceptibility or resistance to malaria in central Africa.
In conclusion, our findings highlight that an HLA-A genetic regulation of specific immune responses may operate at the pre-erythrocytic stage of development of P. falciparum in a given population. This may contribute to individual differences in susceptibility to clinical malaria, some individuals having a reduced capacity to acquire natural immune protection. Such findings must also be taken into account in the context of vaccine development, as the response to sub-unit vaccines is likely to involve similar genetic restriction. Nevertheless, since the recent identification of HLA class I alleles overlapping in their peptide-binding specificity and grouped for this reason into HLA class I supertypes, it seems possible to overcome the stringent specificity of the CD8 + T cell-HLA interactions as well as the high degree of genetic polymorphism of HLA molecules, for the search of a subunit vaccine against pre-erythrocytic stages of P. falciparum. 41 If confirmed, this will reinforce the importance of LSA-1 as a vaccine candidate for large and distinct population groups.
Materials and methods

Study area
The study was conducted in Dienga, a village of 1200 inhabitants located in south eastern Gabon, near the Congo border. This village is situated in a rain forest area, and malaria is highly endemic with peaks of transmission occurring at the end of the rainy seasons from December to March and in July-August. Anopheles gambiae s.l. and An. hancocki are the mosquito species involved in P. falciparum transmission with a mean 0.29 infective mosquito bite per man and per night, as assessed by an entomological survey in 1995-1996 (Elissa N, unpublished data).
Subjects
A clinical, biological and parasitologic follow-up, details of which have been described elsewhere, 23 was carried out from February 1995 to March 1996 (except during the school summer holidays) among the 300 children attending the primary school in Dienga. Clinical data allowed protected and unprotected children to be distinguished. Protected children (n = 76) were defined as those who, during the whole survey period, never presented with a febrile episode (defined by an axillary temperature Ͼ37.5°C) and had neither a P. falciparum parasitemia Ͼ400/l nor 4-aminoquinoline metabolites in their urine. 42 Unprotected children (n = 82) were defined as those who presented with at least one malaria attack, defined by the association of fever with P. falciparum parasitemia Ͼ5000/l. The other children (n = 142) remained unclassified. After obtaining informed consent from all individuals and/or their parents, venous blood samples were taken into Vacutainer EDTA tubes at the beginning of the follow-up for the HLA typing (n = 283 children, mean age ± s.d. = 10.4 ± 2.7) and at the end of the follow-up period for the immunologic assays (n = 229 children, mean age ± s.d. = 10.2 ± 2.6). Ethical clearance for the study was given by the Ethics Committee of the Centre International de Recherches Médicales de Franceville.
HLA typing
High molecular weight DNA was extracted from peripheral blood nucleated cells of 283 children for HLA class II typing. Eighty-two of these children, with an equal distribution of protected and unprotected children, were also typed for HLA class I alleles.
HLA class I PCR-SSP typing:
A generic and semi-specific typing of all HLA-A and -B specificities was performed by PCR-SSP (Sequence Specific Primers) according to the instructions of the suppliers (Dynal France S.A.). Using primer solutions consisting of specific primer mixes, ie, the allele-and group-specific primers as well as control primer pairs matching non-allelic sequences, all the phenotypically different HLA-A and -B alleles recognized by the HLA Nomenclature Committee and grouped into 24 and 48 serologically defined specificities, respectively, were identifiable. 43 HLA class II PCR-RFLP typing: Polymorphic second-exon regions of the HLA-DRB1, -DQA1, -DQB1 and -DPB1 genes were enzymatically amplified by PCR, using the primers and PCR cycling parameters previously described. 35 Restriction endonuclease mapping of the PCR products provides profiles that define the HLA class II alleles at the nucleotide level, and allows identification of 135 major alleles or groups of alleles (grouped into 10 specificities) among the 184 known DRB1 alleles. 43 Similarly, 9, 24 and 53 major alleles or groups of alleles are recognizable out of a total of 19, 35 and 83 DQA1, DQB1 and DPB1 alleles respectively, so far reported in the literature. For each locus, the alleles identified by PCR-RFLP include all major alleles, unidentifiable alleles corresponding to rare or newly described alleles.
Immunologic assays
Cellular immunologic responses were assessed using two synthetic peptides (LAKEKLQEQQSDLEQER) 2 LAKEKLQ (residues 187-227, abbrev.: LSA-Rep) and ERRAKEKLQE QQRDLEQRKADTKK (residues 1613-1636, abbrev.: LSA-J) representing B and T cell epitopes from conserved regions of the LSA-1 antigen from P. falciparum, as well as the peptide KPIVQYDNF (residues 1786-1794, abbrev.: LSA-CTL) representing a conserved CTL epitope from LSA-1. 17 All peptides were purchased from the Pasteur Institute (Paris, France). The assays were conducted as previously described. 24 Briefly, cellular responses were investigated using isolated PBMC from 229 children in a standard lymphocyte proliferative assay (LPA). Data were expressed as stimulation indices (SI), with a threshold of positivity for all peptides of SI Ͼ2.0, restricted to those assays where geometric mean test counts/min Ͼ the geometric mean +2 s.d. of an individual's own background counts/min. Immunoassays for TNF-␣, IL-2 and IL-10 release (on 72 h undiluted culture supernatants) and for IFN-␥ and IL-6 release (on 6-day undiluted culture supernatants) were performed on 103 of the 229 samples, using a two-site ELISA according to the manufacturer's instructions (IFN-␥: Mabtech, Stockholm, Sweden; IL-2: Genzyme, Cambridge, MA, USA; other cytokines: Pharmingen, San Diego, CA, USA). Cytokine concentrations were determined by reference to standard curves prepared with recombinant human cytokines (IL-2: Genzyme, other cytokines: Pharmingen). The thresholds of sensitivity were 8 pg/ml for TNF-␣, IL-2 and ILGenes and Immunity 6 and 2 pg/ml for IFN-␥ and IL-10. Results were expressed as the difference between the cytokine content in stimulated cultures and the spontaneous cytokine content in unstimulated cultures. Therefore, cytokine data represent the amount of cytokine produced in response to stimulation, and may occasionally lie below the mathematical detection limit.
Statistical analysis
For each peptide and each subject, the results of the cellular assays were divided into qualitative variables according to the threshold of positivity of each test. A subject was considered as a cellular responder if at least one positive response was obtained in the LPA and/or one of the cytokine production assays. Differences in proportions were analyzed using contingency tables and Fisher's exact (Chi-square) test. Differences in means were tested by the Student's unpaired t-test on linear or log-transformed values. Where variable distributions were not normalized by log-transformation, the nonparametric Mann-Whitney U-test was employed. Statview 4.5 (Abacus Concept, Berkeley, CA, USA) and programming under Access 7.0 (Microsoft Corporation, Seattle, WA, USA) were used for these calculations. P values Ͻ0.05 were considered significant. Initial analysis involving HLA alleles was computed when a minimum size of six alleles was observed and, given the number of tests, a P value Ͻ0.01 was considered significant.
